{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:44:17Z","timestamp":1782787457257,"version":"3.54.5"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Protoplasma"],"DOI":"10.1007\/s00709-026-02235-5","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:42:49Z","timestamp":1782780169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Probiotics as modulators of the gut-derived incretin peptide axis in type 2 diabetes: GLP-1, GLP-2, and microbial metabolite signaling"],"prefix":"10.1007","author":[{"given":"Ghaleb","family":"Oriquat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-5783","authenticated-orcid":false,"given":"Waleed K.","family":"Abdulsahib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael Waleed","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar B.","family":"Gajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malathi","family":"Hanumanthayya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep Kumar","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashree","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Bainsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saodat","family":"Khaitova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2235_CR1","doi-asserted-by":"crossref","unstructured":"Abbas S, Khan A, Akhtar TS, Samad A, Chinnam S, Mushtaq S, Usman M, Khan A, Akash MSH (2024) Microbiome-Based Treatment for Gastrointestinal Tract Disorders. Human Microbiome: Techniques, Strategies, and Therapeutic Potential. Springer, pp 367\u2013400","DOI":"10.1007\/978-981-97-3790-1_12"},{"issue":"10","key":"2235_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10102061","volume":"10","author":"N Abdalqadir","year":"2022","unstructured":"Abdalqadir N, Adeli K (2022) GLP-1 and GLP-2 orchestrate intestine integrity, gut microbiota, and immune system crosstalk. Microorganisms 10(10):2061","journal-title":"Microorganisms"},{"key":"2235_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10102061","author":"N Abdalqadir","year":"2022","unstructured":"Abdalqadir N, Adeli K (2022) GLP-1 and GLP-2 orchestrate intestine integrity, gut microbiota, and immune system crosstalk. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms10102061","journal-title":"Microorganisms"},{"issue":"7","key":"2235_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41574-025-01114-y","volume":"21","author":"D Accili","year":"2025","unstructured":"Accili D, Deng Z, Liu Q (2025) Insulin resistance in type 2 diabetes mellitus. Nat Rev Endocrinol 21(7):413\u2013426","journal-title":"Nat Rev Endocrinol"},{"key":"2235_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH (2024) Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab 15:20420188231222367","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"2235_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13098-025-01841-2","volume":"17","author":"AR Allam","year":"2025","unstructured":"Allam AR, Helal MB, Alhateem MS, Shehab MA, Elshaar AG, Saeda MA, Ibrahim FM, Khalil AM, Mahmoud AM (2025) Network meta-analysis of randomized control trials evaluating the effectiveness of various probiotic formulations in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 17(1):265","journal-title":"Diabetol Metab Syndr"},{"issue":"2\u20133","key":"2235_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1515\/jbcpp-2025-0031","volume":"36","author":"AA Alluri","year":"2025","unstructured":"Alluri AA, Guntupalli Y, Suvarna SS, Prystupa Y, Khetan SP, Vejandla B, Babu Swathi NL (2025) Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management. J Basic Clin Physiol Pharmacol 36(2\u20133):95\u2013111","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"3","key":"2235_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/jam.14843","volume":"130","author":"TJ Ashaolu","year":"2021","unstructured":"Ashaolu TJ, Ashaolu JO, Adeyeye SA (2021) Fermentation of prebiotics by human colonic microbiota in vitro and short-chain fatty acids production: a critical review. J Appl Microbiol 130(3):677\u2013687","journal-title":"J Appl Microbiol"},{"issue":"10","key":"2235_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108836","volume":"24","author":"R Atanga","year":"2023","unstructured":"Atanga R, Singh V, In JG (2023) Intestinal enteroendocrine cells: present and future druggable targets. Int J Mol Sci 24(10):8836","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2235_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_431818","volume":"44","author":"G Au-Yeung","year":"2024","unstructured":"Au-Yeung G, MacArthur J, Chan J, Ilenkovan N, Frumovitz M, Fader AN, Gourley C (2024) Innovations in rare gynecologic cancer: melanoma, neuroendocrine, and low-grade serous ovarian. Am Soc Clin Oncol Educ Book 44(3):e431818","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"2235_CR11","first-page":"e46741","volume":"15","author":"IE Ayesha","year":"2023","unstructured":"Ayesha IE, Monson NR, Klair N, Patel U, Saxena A, Patel D, Venugopal S (2023a) Probiotics and Their Role in the Management of Type 2 Diabetes Mellitus (Short-Term Versus Long-Term Effect): A Systematic Review and Meta-Analysis. Cureus 15(10):e46741","journal-title":"Cureus"},{"key":"2235_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46741","author":"IE Ayesha","year":"2023","unstructured":"Ayesha IE, Monson NR, Klair N, Patel U, Saxena A, Patel D, Venugopal S, Ayesha IE (2023) Probiotics and their role in the management of type 2 diabetes mellitus (short-term versus long-term effect): a systematic review and meta-analysis. Cureus. https:\/\/doi.org\/10.7759\/cureus.46741","journal-title":"Cureus"},{"issue":"2","key":"2235_CR13","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998287178240403055901","volume":"21","author":"G Barakat","year":"2025","unstructured":"Barakat G, Assi G, Khalil H, El Khatib S (2025) A comprehensive review on GLP-1 signaling pathways in the management of diabetes mellitus-focus on the potential role of GLP-1 receptors agonists and selenium among various organ systems. Curr Diabetes Rev 21(2):E160424228945","journal-title":"Curr Diabetes Rev"},{"issue":"11","key":"2235_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.102172","volume":"32","author":"H Benabdelkamel","year":"2024","unstructured":"Benabdelkamel H, Sebaa R, AlMalki RH, Masood A, Alfadda AA, Rahman AMA (2024) Untargeted metabolomics reveals the impact of Liraglutide treatment on metabolome profiling and metabolic pathways in type-2 diabetes mellitus. Saudi Pharm J 32(11):102172","journal-title":"Saudi Pharm J"},{"key":"2235_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.931458","volume":"9","author":"M Bilal","year":"2022","unstructured":"Bilal M, Ashraf S, Zhao X (2022) Dietary component-induced inflammation and its amelioration by prebiotics, probiotics, and synbiotics. Front Nutr 9:931458","journal-title":"Front Nutr"},{"issue":"1","key":"2235_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00125-020-05295-1","volume":"64","author":"PM Bock","year":"2021","unstructured":"Bock PM, Telo GH, Ramalho R, Sbaraini M, Leivas G, Martins AF, Schaan BD (2021) The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 64(1):26\u201341","journal-title":"Diabetologia"},{"issue":"11","key":"2235_CR17","doi-asserted-by":"publisher","first-page":"bqac159","DOI":"10.1210\/endocr\/bqac159","volume":"163","author":"PL Brubaker","year":"2022","unstructured":"Brubaker PL (2022) The molecular determinants of glucagon-like peptide secretion by the intestinal L cell. Endocrinology 163(11):bqac159","journal-title":"Endocrinology"},{"issue":"4","key":"2235_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s13167-017-0117-3","volume":"8","author":"RV Bubnov","year":"2017","unstructured":"Bubnov RV, Babenko LP, Lazarenko LM, Mokrozub VV, Demchenko OA, Nechypurenko OV, Spivak MY (2017) Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice. EPMA J 8(4):357\u2013376","journal-title":"EPMA J"},{"issue":"8","key":"2235_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/gut.2008.165886","volume":"58","author":"PD Cani","year":"2009","unstructured":"Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58(8):1091\u20131103","journal-title":"Gut"},{"key":"2235_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.662739","volume":"12","author":"MD Carretta","year":"2021","unstructured":"Carretta MD, Quiroga J, L\u00f3pez R, Hidalgo MA, Burgos RA (2021) Participation of short-chain fatty acids and their receptors in gut inflammation and colon cancer. Front Physiol 12:662739","journal-title":"Front Physiol"},{"issue":"18","key":"2235_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186678","volume":"14","author":"A Caturano","year":"2025","unstructured":"Caturano A, Morciano C, Zieli\u0144ska K, Russo V, Perrone MA, Berra CC, Conte C (2025) Rethinking the diabetes\u2013cardiovascular disease continuum: toward integrated care. J Clin Med 14(18):6678","journal-title":"J Clin Med"},{"key":"2235_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jcis.2025.01.051","volume":"684","author":"J Chen","year":"2025","unstructured":"Chen J, Guo Y, Zheng Y, Chen Z, Xu H, Pan S, Liang X, Zhai L, Guan Y-Q (2025) Oral glucose-responsive nanoparticles loaded with artemisinin induce pancreatic \u03b2-cell regeneration for the treatment of type 2 diabetes. J Colloid Interface Sci 684:769\u2013782","journal-title":"J Colloid Interface Sci"},{"key":"2235_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1486793","volume":"15","author":"S Chong","year":"2025","unstructured":"Chong S, Lin M, Chong D, Jensen S, Lau NS (2025) A systematic review on gut microbiota in type 2 diabetes mellitus. Front Endocrinol (Lausanne) 15:1486793","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2235_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010221","volume":"12","author":"VJ Clemente-Su\u00e1rez","year":"2024","unstructured":"Clemente-Su\u00e1rez VJ, Redondo-Fl\u00f3rez L, Rubio-Zarapuz A, Mart\u00edn-Rodr\u00edguez A, Tornero-Aguilera JF (2024) Microbiota implications in endocrine-related diseases: from development to novel therapeutic approaches. Biomedicines 12(1):221","journal-title":"Biomedicines"},{"key":"2235_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.578386","volume":"12","author":"F Cristofori","year":"2021","unstructured":"Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R (2021) Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. Front Immunol 12:578386","journal-title":"Front Immunol"},{"issue":"1","key":"2235_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/fermentation10010006","volume":"10","author":"M de Souza","year":"2023","unstructured":"de Souza M, Drunkler DA, Colla E (2023) Probiotic functional yogurt: challenges and opportunities. Fermentation (Basel) 10(1):6","journal-title":"Fermentation (Basel)"},{"issue":"5","key":"2235_CR27","first-page":"1020","volume":"71","author":"WM De Vos","year":"2022","unstructured":"De Vos WM, Tilg H, Van Hul M, Cani PD (2022) Gut microbiome health: mechanistic insights Gut 71(5):1020\u20131032","journal-title":"Gut microbiome health: mechanistic insights Gut"},{"issue":"2","key":"2235_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","volume":"19","author":"F Di Vincenzo","year":"2024","unstructured":"Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F (2024) Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med 19(2):275\u2013293","journal-title":"Intern Emerg Med"},{"key":"2235_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.770861","volume":"12","author":"L-N Ding","year":"2021","unstructured":"Ding L-N, Ding W-Y, Ning J, Wang Y, Yan Y, Wang Z-B (2021) Effects of probiotic supplementation on inflammatory markers and glucose homeostasis in adults with type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol 12:770861","journal-title":"Front Pharmacol"},{"key":"2235_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ (2022) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351","journal-title":"Mol Metab"},{"key":"2235_CR31","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ (2022b) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351","journal-title":"Mol Metab"},{"key":"2235_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1618275","volume":"12","author":"DA Dua","year":"2025","unstructured":"Dua DA, Kumari R, Singh M, Kumar R, Pradeep S, Ojesina AI, Kumar R (2025) Metabolic dysfunction-associated steatotic liver disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes. Front Med 12:1618275","journal-title":"Front Med"},{"key":"2235_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1091757","volume":"9","author":"N Ebrahim","year":"2022","unstructured":"Ebrahim N, Shakirova K, Dashinimaev E (2022) PDX1 is the cornerstone of pancreatic \u03b2-cell functions and identity. Front Mol Biosci 9:1091757","journal-title":"Front Mol Biosci"},{"issue":"12","key":"2235_CR34","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.3390\/ijms26125486","volume":"26","author":"Y Fan","year":"2025","unstructured":"Fan Y, Liu Y, Shao C, Jiang C, Wu L, Xiao J, Tang L (2025) Gut microbiota-targeted therapeutics for metabolic disorders: mechanistic insights into the synergy of probiotic-fermented herbal bioactives. Int J Mol Sci 26(12):5486","journal-title":"Int J Mol Sci"},{"key":"2235_CR35","unstructured":"Federation ID (2021) IDF diabetes atlas 10th"},{"issue":"7 Suppl","key":"2235_CR36","first-page":"S187","volume":"16","author":"AJ Garber","year":"2010","unstructured":"Garber AJ (2010a) Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care 16(7 Suppl):S187\u2013194","journal-title":"Am J Manag Care"},{"issue":"7","key":"2235_CR37","first-page":"S187","volume":"16","author":"AJ Garber","year":"2010","unstructured":"Garber AJ (2010b) Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Managed Care 16(7):S187","journal-title":"Am J Managed Care"},{"issue":"1","key":"2235_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41378-024-00743-z","volume":"10","author":"A Gholami","year":"2024","unstructured":"Gholami A, Mohkam M, Soleimanian S, Sadraeian M, Lauto A (2024) Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy. Microsyst Nanoeng 10(1):113","journal-title":"Microsyst Nanoeng"},{"issue":"8","key":"2235_CR39","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/nu17081303","volume":"17","author":"KK Gofron","year":"2025","unstructured":"Gofron KK, Wasilewski A, Ma\u0142gorzewicz S (2025a) Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review. Nutrients 17(8):1303","journal-title":"Nutrients"},{"key":"2235_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/nu17081303","author":"KK Gofron","year":"2025","unstructured":"Gofron KK, Wasilewski A, Ma\u0142gorzewicz S (2025) Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review. Nutrients. https:\/\/doi.org\/10.3390\/nu17081303","journal-title":"Nutrients"},{"key":"2235_CR41","unstructured":"Greco G (2021) Regulation of the epithelial barrier in the rumen epithelium of sheep by incubation with single short-chain fatty acid at different pH, with glucagon-like peptide 1, glucagon-like peptide 2, and epidermal growth factor"},{"issue":"10","key":"2235_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009959","volume":"17","author":"AL Gregory","year":"2021","unstructured":"Gregory AL, Pensinger DA, Hryckowian AJ (2021) A short chain fatty acid\u2013centric view of Clostridioides difficile pathogenesis. PLoS Pathog 17(10):e1009959","journal-title":"PLoS Pathog"},{"key":"2235_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051436","author":"S Gul","year":"2024","unstructured":"Gul S, Durante-Mangoni E (2024) Unraveling the puzzle: health benefits of probiotics-a comprehensive review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13051436","journal-title":"J Clin Med"},{"issue":"43","key":"2235_CR44","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.3748\/wjg.v30.i43.4682","volume":"30","author":"M Guney-Coskun","year":"2024","unstructured":"Guney-Coskun M, Basaranoglu M (2024a) Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: new frontiers in metabolic dysfunction-associated steatotic liver disease therapy. World J Gastroenterol 30(43):4682","journal-title":"World J Gastroenterol"},{"issue":"43","key":"2235_CR45","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.3748\/wjg.v30.i43.4682","volume":"30","author":"M Guney-Coskun","year":"2024","unstructured":"Guney-Coskun M, Basaranoglu M (2024b) Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy. World J Gastroenterol 30(43):4682\u20134688","journal-title":"World J Gastroenterol"},{"key":"2235_CR46","doi-asserted-by":"crossref","unstructured":"Huang H, Ma D, Zhou Y, Wu L (2025) Effect of probiotics and related supplements on glycemic control in pediatric patients with type 1 diabetes mellitus: a systematic review and meta-analysis of clinical trials. Front Pediatr Volume 13\u20132025","DOI":"10.3389\/fped.2025.1633694"},{"issue":"23","key":"2235_CR47","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1113\/JP281356","volume":"599","author":"H Islam","year":"2021","unstructured":"Islam H, Neudorf H, Mui AL, Little JP (2021) Interpreting \u2018anti-inflammatory\u2019cytokine responses to exercise: focus on interleukin-10. J Physiol 599(23):5163\u20135177","journal-title":"J Physiol"},{"issue":"3","key":"2235_CR48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/fbe2.12098","volume":"3","author":"S Jain","year":"2024","unstructured":"Jain S, Shukla AK, Deepika S, Panwar A, Kumari AK, Yadav, Kumar A (2024) Revolutionizing disease treatment through bioengineered probiotics and glucagon-like peptide 1 (GLP\u20101) based strategies: A path towards effective cures. Food Bioeng 3(3):280\u2013300","journal-title":"Food Bioeng"},{"issue":"15","key":"2235_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157797","volume":"22","author":"JA Janssen","year":"2021","unstructured":"Janssen JA (2021) Hyperinsulinemia and its pivotal role in aging, obesity, type 2 diabetes, cardiovascular disease and cancer. Int J Mol Sci 22(15):7797","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2235_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.420","volume":"4","author":"J Ji","year":"2023","unstructured":"Ji J, Jin W, Liu SJ, Jiao Z, Li X (2023) Probiotics, prebiotics, and postbiotics in health and disease. MedComm (2020) 4(6):e420","journal-title":"MedComm (2020)"},{"issue":"7","key":"2235_CR51","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/s41401-023-01215-2","volume":"45","author":"C Jin","year":"2024","unstructured":"Jin C, Chen H, Xie L, Zhou Y, Liu L-l, Wu J (2024) GPCRs involved in metabolic diseases: pharmacotherapeutic development updates. Acta Pharmacol Sin 45(7):1321\u20131336","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"2235_CR52","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bph.15497","volume":"179","author":"B Jones","year":"2022","unstructured":"Jones B (2022) The therapeutic potential of GLP-1 receptor biased agonism. Br J Pharmacol 179(4):492\u2013510","journal-title":"Br J Pharmacol"},{"issue":"11","key":"2235_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12111064","volume":"12","author":"M Kandpal","year":"2022","unstructured":"Kandpal M, Indari O, Baral B, Jakhmola S, Tiwari D, Bhandari V, Pandey RK, Bala K, Sonawane A, Jha HC (2022) Dysbiosis of gut microbiota from the perspective of the gut\u2013brain axis: role in the provocation of neurological disorders. Metabolites 12(11):1064","journal-title":"Metabolites"},{"issue":"8","key":"2235_CR54","doi-asserted-by":"publisher","first-page":"e0282824","DOI":"10.1128\/spectrum.02828-24","volume":"13","author":"Z Ke","year":"2025","unstructured":"Ke Z, Ma Q, Ye X, Jin Y, Wang Y, Zhao X, Su Z (2025a) Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus. Microbiol Spectr 13(8):e0282824","journal-title":"Microbiol Spectr"},{"issue":"8","key":"2235_CR55","doi-asserted-by":"publisher","first-page":"e02828","DOI":"10.1128\/spectrum.02828-24","volume":"13","author":"Z Ke","year":"2025","unstructured":"Ke Z, Ma Q, Ye X, Jin Y, Wang Y, Zhao X, Su Z (2025) Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus. Microbiol Spectr 13(8):e02828-02824","journal-title":"Microbiol Spectr"},{"issue":"5","key":"2235_CR56","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/1040841X.2023.2257776","volume":"50","author":"N Kobyliak","year":"2024","unstructured":"Kobyliak N, Khomenko M, Falalyeyeva T, Fedchenko A, Savchuk O, Tseyslyer Y, Ostapchenko L (2024) Probiotics for pancreatic \u03b2-cell function: from possible mechanism of action to assessment of effectiveness. Crit Rev Microbiol 50(5):663\u2013683","journal-title":"Crit Rev Microbiol"},{"key":"2235_CR57","doi-asserted-by":"publisher","first-page":"694284","DOI":"10.3389\/fendo.2021.694284","volume":"12","author":"RE Kuhre","year":"2021","unstructured":"Kuhre RE, Deacon CF, Holst JJ, Petersen N (2021) What is an L-cell and how do we study the secretory mechanisms of the L-cell? Front Endocrinol 12:694284","journal-title":"Front Endocrinol"},{"issue":"1","key":"2235_CR58","first-page":"94","volume":"8","author":"OP Lawal","year":"2025","unstructured":"Lawal OP, Adekunle JF, Abiodun AV, Orobator ET, Agbo OS, Ugoagwu KU, Akintayo EA, Olaniyi AO, Otabil C, Mandal M (2025) Modulating gut microbiota for precision medicine in diabetes: a paradigm shift in personalized treatment strategies. Asian J Res Rep Endocrinol 8(1):94\u2013109","journal-title":"Asian J Res Rep Endocrinol"},{"issue":"3","key":"2235_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101493","volume":"35","author":"R Li","year":"2021","unstructured":"Li R, Andreu-S\u00e1nchez S, Kuipers F, Fu J (2021) Gut microbiome and bile acids in obesity-related diseases. Best Pract Res Clin Endocrinol Metab 35(3):101493","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2235_CR60","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12967-023-04306-0","volume":"21","author":"G Li","year":"2023","unstructured":"Li G, Feng H, Mao XL, Deng YJ, Wang XB, Zhang Q, Guo Y, Xiao SM (2023) The effects of probiotics supplementation on glycaemic control among adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials. J Transl Med 21(1):442","journal-title":"J Transl Med"},{"issue":"19","key":"2235_CR61","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1080\/10408398.2023.2169858","volume":"64","author":"D Liang","year":"2024","unstructured":"Liang D, Wu F, Zhou D, Tan B, Chen T (2024) Commercial probiotic products in public health: current status and potential limitations. Crit Rev Food Sci Nutr 64(19):6455\u20136476","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"4","key":"2235_CR62","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11154-020-09586-1","volume":"21","author":"Y Lin","year":"2020","unstructured":"Lin Y, Zhang Z, Wang S, Cai J, Guo J (2020) Hypothalamus-pituitary-adrenal axis in glucolipid metabolic disorders. Rev Endocr Metab Disord 21(4):421\u2013429","journal-title":"Rev Endocr Metab Disord"},{"key":"2235_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116906","volume":"237","author":"M Lin","year":"2025","unstructured":"Lin M, Wang L, Guan B, Tang S, Lin L, Wu K, Huang Q, He G, Zhang Z, Gao R (2025) Effect of PAI-1 inhibitor on pancreatic islet function and hepatic insulin resistance in db\/db mice. Biochem Pharmacol 237:116906","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2235_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01951-9","volume":"9","author":"X Lu","year":"2024","unstructured":"Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, Zhang Y, Shen S, Tong N (2024) Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther 9(1):262","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2235_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063303","volume":"23","author":"A Lymperopoulos","year":"2022","unstructured":"Lymperopoulos A, Suster MS, Borges JI (2022) Short-chain fatty acid receptors and cardiovascular function. Int J Mol Sci 23(6):3303","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2235_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42000-020-00236-4","volume":"20","author":"AP Makris","year":"2021","unstructured":"Makris AP, Karianaki M, Tsamis KI, Paschou SA (2021) The role of the gut-brain axis in depression: endocrine, neural, and immune pathways. Hormones Athens 20(1):1\u201312","journal-title":"Hormones Athens"},{"key":"2235_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1169624","volume":"14","author":"KE Masse","year":"2023","unstructured":"Masse KE, Lu VB (2023) Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease. Front Endocrinol 14:1169624","journal-title":"Front Endocrinol"},{"key":"2235_CR68","unstructured":"Meyer R (2025) Metabolites Produced or Altered by the Gut Microbiota Impact Metabolic Homeostasis. The University of Arizona"},{"issue":"11","key":"2235_CR69","doi-asserted-by":"publisher","first-page":"9181","DOI":"10.3390\/cimb45110576","volume":"45","author":"AN Miliotou","year":"2023","unstructured":"Miliotou AN, Georgiou-Siafis SK, Ntenti C, Pappas IS, Papadopoulou LC (2023) Recruiting in vitro transcribed mRNA against cancer immunotherapy: a contemporary appraisal of the current landscape. Curr Issues Mol Biol 45(11):9181\u20139214","journal-title":"Curr Issues Mol Biol"},{"key":"2235_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1358625","author":"K Mukherjee","year":"2024","unstructured":"Mukherjee K, Xiao C (2024) GLP-2 regulation of intestinal lipid handling. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2024.1358625","journal-title":"Front Physiol"},{"issue":"3","key":"2235_CR71","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrm2327","volume":"9","author":"DM Muoio","year":"2008","unstructured":"Muoio DM, Newgard CB (2008) Molecular and metabolic mechanisms of insulin resistance and \u03b2-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9(3):193\u2013205","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"13","key":"2235_CR72","doi-asserted-by":"publisher","first-page":"18408","DOI":"10.1007\/s11356-022-18534-2","volume":"29","author":"NE Nasr","year":"2022","unstructured":"Nasr NE, Sadek KM (2022) Role and mechanism (s) of incretin-dependent therapies for treating diabetes mellitus. Environ Sci Pollut Res 29(13):18408\u201318422","journal-title":"Environ Sci Pollut Res"},{"issue":"10","key":"2235_CR73","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","volume":"66","author":"MA Nauck","year":"2023","unstructured":"Nauck MA, M\u00fcller TD (2023) Incretin hormones and type 2 diabetes. Diabetologia 66(10):1780\u20131795","journal-title":"Diabetologia"},{"key":"2235_CR74","doi-asserted-by":"crossref","unstructured":"Ottaviano G, Qasim W (2025a) Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy. Leukemia: 1\u20139","DOI":"10.1038\/s41375-025-02585-8"},{"issue":"6","key":"2235_CR75","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41375-025-02585-8","volume":"39","author":"G Ottaviano","year":"2025","unstructured":"Ottaviano G, Qasim W (2025) Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy: genomics and gene therapy. Leukemia 39(6):1325\u20131333","journal-title":"Leukemia"},{"issue":"1","key":"2235_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-023-03640-z","volume":"84","author":"Y Pan","year":"2024","unstructured":"Pan Y, Bu T, Deng X, Jia J, Yuan G (2024) Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis. Endocrine 84(1):1\u201315","journal-title":"Endocrine"},{"key":"2235_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00584","volume":"9","author":"S Paternoster","year":"2018","unstructured":"Paternoster S, Falasca M (2018) Dissecting the physiology and pathophysiology of glucagon-like peptide-1. Front Endocrinol (Lausanne) 9:584","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2235_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041773","volume":"26","author":"E Pe\u00f1a-Dur\u00e1n","year":"2025","unstructured":"Pe\u00f1a-Dur\u00e1n E, Garc\u00eda-Galindo JJ, L\u00f3pez-Murillo LD, Huerta-Huerta A, Balleza-Alejandri LR, Beltr\u00e1n-Ram\u00edrez A, Anaya-Ambriz EJ, Su\u00e1rez-Rico DO (2025) Microbiota and inflammatory markers: a review of their interplay, clinical implications, and metabolic disorders. Int J Mol Sci 26(4):1773","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2235_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/app14209383","volume":"14","author":"L Pires","year":"2024","unstructured":"Pires L, Gonzalez-Param\u00e1s AM, Heleno SA, Calhelha RC (2024) Gut microbiota as an endocrine organ: unveiling its role in human physiology and health. Appl Sci 14(20):9383","journal-title":"Appl Sci"},{"issue":"suppl_1","key":"2235_CR80","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/advances\/nmy063","volume":"10","author":"J Plaza-Diaz","year":"2019","unstructured":"Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A (2019) Mechanisms of action of probiotics. Adv Nutr 10(suppl_1):S49-s66","journal-title":"Adv Nutr"},{"issue":"11","key":"2235_CR81","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.3390\/ijms25115640","volume":"25","author":"P Portincasa","year":"2024","unstructured":"Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, Baffy G, Di Ciaula A (2024) Metabolic dysfunction\u2013associated steatotic liver disease: from pathogenesis to current therapeutic options. Int J Mol Sci 25(11):5640","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2235_CR82","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1111\/1541-4337.12808","volume":"20","author":"W Qin","year":"2021","unstructured":"Qin W, Ying W, Hamaker B, Zhang G (2021) Slow digestion-oriented dietary strategy to sustain the secretion of GLP\u20101 for improved glucose homeostasis. Compr Rev Food Sci Food Saf 20(5):5173\u20135196","journal-title":"Compr Rev Food Sci Food Saf"},{"key":"2235_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.phanu.2023.100342","volume":"24","author":"K Rani","year":"2023","unstructured":"Rani K, Kaur G, Ali SA (2023) Probiotic-prebiotic therapeutic potential: a new horizon of microbial biotherapy to reduce female reproductive complications. PharmaNutrition 24:100342","journal-title":"PharmaNutrition"},{"issue":"2","key":"2235_CR84","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/JOE-20-0473","volume":"248","author":"M R\u00e9gnier","year":"2021","unstructured":"R\u00e9gnier M, Van Hul M, Knauf C, Cani PD (2021) Gut microbiome, endocrine control of gut barrier function and metabolic diseases. J Endocrinol 248(2):R67\u2013R82","journal-title":"J Endocrinol"},{"issue":"5","key":"2235_CR85","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/jpen.2286","volume":"46","author":"J Reiner","year":"2022","unstructured":"Reiner J, Berlin P, Held J, Thiery J, Skarbaliene J, Griffin J, Russell W, Eriksson PO, Berner-Hansen M, Ehlers L, Vollmar B, Jaster R, Witte M, Lamprecht G (2022) Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. JPEN J Parenter Enteral Nutr 46(5):1107\u20131118","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"14","key":"2235_CR86","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3748\/wjg.v29.i14.2078","volume":"29","author":"S Roy","year":"2023","unstructured":"Roy S, Dhaneshwar S (2023) Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: current perspectives. World J Gastroenterol 29(14):2078","journal-title":"World J Gastroenterol"},{"issue":"Supplement_2","key":"2235_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.3056","volume":"41","author":"G Ruotolo","year":"2020","unstructured":"Ruotolo G, Roth K, Milligan P, Lin Y, Wilson J, Pirro V, Duffin K, Haupt A (2020) Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes. Eur Heart J 41(Supplement_2):ehaa946. 3056","journal-title":"Eur Heart J"},{"issue":"1","key":"2235_CR88","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4239\/wjd.v6.i1.109","volume":"6","author":"Y Saisho","year":"2015","unstructured":"Saisho Y (2015) \u03b2-cell dysfunction: its critical role in prevention and management of type 2 diabetes. World J Diabetes 6(1):109","journal-title":"World J Diabetes"},{"key":"2235_CR89","doi-asserted-by":"crossref","unstructured":"Schneider E, Hangasky J, Ashley G, Santi D (2024) Long-Acting. Longer-Acting and Ultralong-Acting Peptides.","DOI":"10.20944\/preprints202410.0475.v1"},{"issue":"2","key":"2235_CR90","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1007\/s12602-025-10644-w","volume":"18","author":"A Setayesh","year":"2026","unstructured":"Setayesh A, Karimi M, Karimi MA, Pirzad S, Heydari M, Asbaghi O, Davoodi SH, Larijani B (2026) Effects of probiotic and synbiotic supplementation on glycemic indices in adult individuals with prediabetes and type 2 diabetes mellitus: a grade-assessed systematic review and dose\u2013response meta-analysis of RCTs. Probiotics Antimicrob Proteins 18(2):3181\u20133204","journal-title":"Probiotics Antimicrob Proteins"},{"key":"2235_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100419","volume":"28","author":"N Shalbaf","year":"2025","unstructured":"Shalbaf N, Sadeghi S, Homaee S, Saberian F (2025) Probiotics, prebiotics, synbiotics, and FMT for glycemic control: a systematic review of clinical efficacy and mechanistic readouts in type 2 diabetes and related dysglycemia. Metab Open 28:100419","journal-title":"Metab Open"},{"key":"2235_CR92","doi-asserted-by":"publisher","first-page":"1637589","DOI":"10.3389\/fbioe.2025.1637589","volume":"13","author":"S Singaravelu","year":"2025","unstructured":"Singaravelu S, Motsoene F, Abrahamse H, Dhilip Kumar SS (2025) Green-synthesized metal nanoparticles: a promising approach for accelerated wound healing. Front Bioeng Biotechnol 13:1637589","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"2235_CR93","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41522-024-00610-9","volume":"10","author":"X Sun","year":"2024","unstructured":"Sun X, Shukla M, Wang W, Li S (2024) Unlocking gut-liver-brain axis communication metabolites: energy metabolism, immunity and barriers. NPJ Biofilms Microbiomes 10(1):136","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"1","key":"2235_CR94","first-page":"6632266","volume":"2021","author":"R Tang","year":"2021","unstructured":"Tang R, Li L (2021) Modulation of short-chain fatty acids as potential therapy method for type 2 diabetes mellitus. Can J Infect Dis Med Microbiol 2021(1):6632266","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"1","key":"2235_CR95","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12967-020-02213-2","volume":"18","author":"YW Tao","year":"2020","unstructured":"Tao YW, Gu YL, Mao XQ, Zhang L, Pei YF (2020) Effects of probiotics on type II diabetes mellitus: a meta-analysis. J Transl Med 18(1):30","journal-title":"J Transl Med"},{"issue":"10","key":"2235_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102611","volume":"11","author":"J Tokarek","year":"2023","unstructured":"Tokarek J, Budny E, Saar M, Sta\u0144czak K, Wojtanowska E, M\u0142ynarska E, Rysz J, Franczyk B (2023) Molecular processes involved in the shared pathways between cardiovascular diseases and diabetes. Biomedicines 11(10):2611","journal-title":"Biomedicines"},{"issue":"2","key":"2235_CR97","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2337\/db11-1019","volume":"61","author":"G Tolhurst","year":"2012","unstructured":"Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61(2):364\u2013371","journal-title":"Diabetes"},{"issue":"1Suppl 1","key":"2235_CR98","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/dom.16273","volume":"27","author":"T Toshimitsu","year":"2025","unstructured":"Toshimitsu T, Irie J (2025) An update and overview of the various health-related benefits of probiotics: A focus on clinical trials demonstrating efficacy, tolerability and use in patients with impaired glucose tolerance and type 2 diabetes. Diabetes Obes Metab 27(1Suppl 1):15\u201322","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2235_CR99","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/life15060843","volume":"15","author":"V Trapanese","year":"2025","unstructured":"Trapanese V, Dagostino A, Natale MR, Giofr\u00e8 F, Vatalaro C, Melina M, Cosentino F, Sergi S, Imoletti F, Spagnuolo R (2025a) Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies. Life 15(6):843","journal-title":"Life"},{"key":"2235_CR100","doi-asserted-by":"crossref","unstructured":"Trapanese V, Dagostino A, Natale MR, Giofr\u00e8 F, Vatalaro C, Melina M, Cosentino F, Sergi S, Imoletti F, Spagnuolo R, Arturi F (2025b) Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies. Life (Basel) 15(6)","DOI":"10.3390\/life15060843"},{"key":"2235_CR101","unstructured":"Vagaggini C (2024) Characterization of in vitro and in vivo properties of pharmacologically active compounds in a. GLP-Like laboratory."},{"issue":"7","key":"2235_CR102","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/antiox14070767","volume":"14","author":"MDM Viana","year":"2025","unstructured":"Viana MDM, Santos SS, Cruz ABO, Jesus M, Lauria PSS, Lins MP, Villarreal CF (2025) Probiotics as antioxidant strategy for managing diabetes mellitus and its complications. Antioxidants (Basel) 14(7):767","journal-title":"Antioxidants (Basel)"},{"key":"2235_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/nu15030670","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang X, Xiao X, Yu S, Huang W, Rao B, Chen F (2023) A single strain of Lactobacillus (CGMCC 21661) exhibits stable glucose- and lipid-lowering effects by regulating gut microbiota. Nutrients. https:\/\/doi.org\/10.3390\/nu15030670","journal-title":"Nutrients"},{"issue":"11","key":"2235_CR105","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1080\/10408398.2022.2132377","volume":"64","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ai Z, Xing X, Fan Y, Zhang Y, Nan B, Li X, Wang Y, Liu J (2024b) The ameliorative effect of probiotics on diet-induced lipid metabolism disorders: A review. Crit Rev Food Sci Nutr 64(11):3556\u20133572","journal-title":"Crit Rev Food Sci Nutr"},{"key":"2235_CR116","doi-asserted-by":"crossref","unstructured":"Wang J, Teng M, Feng R, Su X, Xu K, Wang J, Wang G, Zhang Y, Xu P (2024a) Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study. Diabetol Metab Syndr 16(1):66","DOI":"10.1186\/s13098-024-01298-9"},{"key":"2235_CR107","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.physbeh.2018.03.004","volume":"192","author":"P Wismann","year":"2018","unstructured":"Wismann P, Pedersen SL, Hansen G, Mannerstedt K, Pedersen PJ, Jeppesen PB, Vrang N, Fosgerau K, Jelsing J (2018) Novel GLP-1\/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. Physiol Behav 192:72\u201381","journal-title":"Physiol Behav"},{"key":"2235_CR108","doi-asserted-by":"publisher","first-page":"856485","DOI":"10.3389\/fcdhc.2022.856485","volume":"3","author":"A Wretlind","year":"2022","unstructured":"Wretlind A, Zobel EH, de Zawadzki A, Ripa RS, Curovic VR, von Scholten BJ, Mattila IM, Hansen TW, Kj\u00e6r A, Vestergaard H (2022) Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Front Clin Diabetes Healthc 3:856485","journal-title":"Front Clin Diabetes Healthc"},{"issue":"5","key":"2235_CR109","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/gutjnl-2019-319146","volume":"69","author":"Y Xu","year":"2020","unstructured":"Xu Y, Van Hul M, Suriano F, Pr\u00e9at V, Cani PD, Beloqui A (2020) Novel strategy for oral peptide delivery in incretin-based diabetes treatment. Gut 69(5):911\u2013919","journal-title":"Gut"},{"issue":"1","key":"2235_CR110","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41392-023-01673-4","volume":"8","author":"M Yan","year":"2023","unstructured":"Yan M, Man S, Sun B, Ma L, Guo L, Huang L, Gao W (2023) Gut liver brain axis in diseases: the implications for therapeutic interventions. Signal transduction and targeted therapy 8(1):443","journal-title":"Signal transduction and targeted therapy"},{"key":"2235_CR111","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.3389\/fmicb.2019.02176","volume":"10","author":"J-M Zhang","year":"2019","unstructured":"Zhang J-M, Sun Y-S, Zhao L-Q, Chen T-T, Fan M-N, Jiao H-C, Zhao J-P, Wang X-J, Li F-C, Li H-F (2019a) SCFAs-induced GLP-1 secretion links the regulation of gut microbiome on hepatic lipogenesis in chickens. Front Microbiol 10:2176","journal-title":"Front Microbiol"},{"key":"2235_CR112","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.3389\/fmicb.2019.02176","volume":"10","author":"JM Zhang","year":"2019","unstructured":"Zhang JM, Sun YS, Zhao LQ, Chen TT, Fan MN, Jiao HC, Zhao JP, Wang XJ, Li FC, Li HF, Lin H (2019b) SCFAs-Induced GLP-1 Secretion Links the Regulation of Gut Microbiome on Hepatic Lipogenesis in Chickens. Front Microbiol 10:2176","journal-title":"Front Microbiol"},{"issue":"8","key":"2235_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202400962","volume":"26","author":"T Zhang","year":"2025","unstructured":"Zhang T, Liu S, He S, Shi L, Ma R (2025) Strategies to enhance the therapeutic efficacy of GLP-1 receptor agonists through structural modification and carrier delivery. ChemBioChem 26(8):e202400962","journal-title":"ChemBioChem"},{"issue":"1","key":"2235_CR114","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):234","journal-title":"Signal Transduct Target Ther"},{"key":"2235_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1364280","volume":"15","author":"P Zhou","year":"2024","unstructured":"Zhou P, Hao Z, Chen Y, Zhang Z, Xu W, Yu J (2024) Association between gut microbiota and diabetic microvascular complications: a two-sample Mendelian randomization study. Front Endocrinol 15:1364280","journal-title":"Front Endocrinol"}],"container-title":["Protoplasma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00709-026-02235-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00709-026-02235-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00709-026-02235-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:02:58Z","timestamp":1782784978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00709-026-02235-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":114,"alternative-id":["2235"],"URL":"https:\/\/doi.org\/10.1007\/s00709-026-02235-5","relation":{},"ISSN":["0033-183X","1615-6102"],"issn-type":[{"value":"0033-183X","type":"print"},{"value":"1615-6102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}